Stock Events

Stock Events

Abivax 

$110.98
0
-$1.16-1.03% Thursday 07:58

Statistics

Day High
113.01
Day Low
110.88
52W High
-
52W Low
-
Volume
16,523
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MayExpected
Q3 2025
Q4 2025
Next
-2.46
-1.91
-1.35
-0.8
Expected EPS
-0.92977014306
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-367.82MNet Income

Analyst Ratings

$145.56Average Price Target
The highest estimate is 176.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
11%
Sell
11%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABVX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
CEO
ISIN
US00370M1036

Listings

F
DE
2X10.F
XETRA
DE
2X1.XETRA
OTC Link
US
AAVXF
BOATS
BOATS
ABVX.BOATS

0 Comments

Share your thoughts

FAQ

What is Abivax stock price today?▼
The current price of ABVX.BOATS is $110.98 USD — it has decreased by -1.03% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abivax stocks are traded under the ticker ABVX.BOATS.
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on May 25, 2026.
What were Abivax earnings last quarter?▼
ABVX.BOATS earnings for the last quarter are -1.22 USD per share, whereas the estimation was -1.36 USD resulting in a +10.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 USD.
What is Abivax net income for the last year?▼
ABVX.BOATS net income for the last year is -367.82M USD.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.